Visual Evoked Potentials (VEP), or visually evoked potentials, are electrical responses that occur in response to a visual stimulating stimulus. These responses occur within the occipital lobe of the brain and are the result of neurons responding to a change in their environment. VEPs are typically measured by using an electroencephalography (EEG) technique that records small amplitude charge in the brain's electrical activity in response to a visual display. Visual Evoked Potentials provide information about the electrical activity of the visual system related to the processing of the eyelids, the visual pathway, and the visual cortex. It is used to examine the functioning of the central visual pathways by measuring the electrical activity of the brain in response to a visual stimulus. A variety of stimuli, including colors, patterns, and flashes, can be used as visual postulates for the measurement of VEPs. VEPs are useful for assessing different aspects of vision, including color recognition, spatial awareness, contrast sensitivity, and visual acuity. The efficiency of the transmission of visual information along the visual pathways and the integrity of its neural connections can also be accessed by these measurements. VEPs are used to identify neurological conditions and diseases that affect the visual pathways. Conditions such as glaucoma, cataracts, retinal disease, occipital lobe damage, and optic neuritis can be assessed with VEPs. Similarly, VEPs can be used to diagnose and monitor traumatic brain injuries, multiple sclerosis, and other brain-related diseases. VEPs are also used to monitor the progress of children with various developmental disabilities, including autism. Visual Evoked Potentials are commonly used for the prevention, diagnosis, and rehabilitation of vision-related disorders. It is a reliable, safe, and noninvasive method for the evaluation of visual pathways and has been popular for years due to its cost- and time-efficiency.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States